DK4103178T3 - Fremgangsmåder til behandling af fabrys sygdom - Google Patents

Fremgangsmåder til behandling af fabrys sygdom

Info

Publication number
DK4103178T3
DK4103178T3 DK21753606.9T DK21753606T DK4103178T3 DK 4103178 T3 DK4103178 T3 DK 4103178T3 DK 21753606 T DK21753606 T DK 21753606T DK 4103178 T3 DK4103178 T3 DK 4103178T3
Authority
DK
Denmark
Prior art keywords
treating
methods
fabrys
disease
fabrys disease
Prior art date
Application number
DK21753606.9T
Other languages
English (en)
Inventor
Nina Skuban
Original Assignee
Amicus Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amicus Therapeutics Inc filed Critical Amicus Therapeutics Inc
Application granted granted Critical
Publication of DK4103178T3 publication Critical patent/DK4103178T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00Measuring for diagnostic purposes; Identification of persons
    • A61B5/42Detecting, measuring or recording for evaluating the gastrointestinal, the endocrine or the exocrine systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00Measuring for diagnostic purposes; Identification of persons
    • A61B5/48Other medical applications
    • A61B5/4848Monitoring or testing the effects of treatment, e.g. of medication
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Medical Informatics (AREA)
  • Surgery (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Pathology (AREA)
  • Biomedical Technology (AREA)
  • Physiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
DK21753606.9T 2020-02-10 2021-02-10 Fremgangsmåder til behandling af fabrys sygdom DK4103178T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202062972392P 2020-02-10 2020-02-10
PCT/US2021/017446 WO2021163183A1 (en) 2020-02-10 2021-02-10 Methods of treating fabry disease

Publications (1)

Publication Number Publication Date
DK4103178T3 true DK4103178T3 (da) 2026-03-30

Family

ID=77272302

Family Applications (1)

Application Number Title Priority Date Filing Date
DK21753606.9T DK4103178T3 (da) 2020-02-10 2021-02-10 Fremgangsmåder til behandling af fabrys sygdom

Country Status (11)

Country Link
US (1) US20210251972A1 (da)
EP (2) EP4732901A2 (da)
JP (1) JP2023513700A (da)
KR (1) KR20220150902A (da)
AU (1) AU2021218578A1 (da)
CA (1) CA3167476A1 (da)
DK (1) DK4103178T3 (da)
FI (1) FI4103178T3 (da)
LT (1) LT4103178T (da)
PT (1) PT4103178T (da)
WO (1) WO2021163183A1 (da)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3224546C (en) 2017-05-30 2026-02-24 Amicus Therapeutics, Inc. Use of migalastat in the treatment of fabry patients
KR20200128676A (ko) 2018-02-06 2020-11-16 아미쿠스 세라퓨틱스, 인코포레이티드 임신 환자의 파브리병 치료를 위한 미갈라스타트의 용도
US12594268B2 (en) * 2018-08-20 2026-04-07 Amicus Therapeutics, Inc. Methods of treating Fabry disease in patients having a mutation in the GLA gene
KR20220044560A (ko) 2019-08-07 2022-04-08 아미쿠스 세라퓨틱스, 인코포레이티드 Gla 유전자에 돌연변이를 갖는 환자에서 파브리 질병을 치료하는 방법
US11623916B2 (en) 2020-12-16 2023-04-11 Amicus Therapeutics, Inc. Highly purified batches of pharmaceutical grade migalastat and methods of producing the same

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6274597B1 (en) 1998-06-01 2001-08-14 Mount Sinai School Of Medicine Of New York University Method of enhancing lysosomal α-Galactosidase A
MX2009010557A (es) 2007-03-30 2009-11-19 Amicus Therapeutics Inc Metodo para el tratamiento de la enfermedad de fabry que utiliza chaperonas farmacologicas.
US9999618B2 (en) * 2007-04-26 2018-06-19 Amicus Therapeutics, Inc. Dosing regimens for the treatment of lysosomal storage diseases using pharmacological chaperones
EP2946785B1 (en) 2008-02-12 2018-10-24 Amicus Therapeutics, Inc. Method to predict response to pharmacological chaperone treatment of diseases
TW202408513A (zh) * 2016-07-19 2024-03-01 美商阿米庫斯醫療股份有限公司 治療ert初治的和已經歷ert的患者中之法布瑞氏症

Also Published As

Publication number Publication date
CA3167476A1 (en) 2021-08-19
LT4103178T (lt) 2026-04-10
EP4732901A2 (en) 2026-04-29
FI4103178T3 (fi) 2026-03-23
EP4103178A1 (en) 2022-12-21
EP4103178B1 (en) 2025-12-24
AU2021218578A1 (en) 2022-08-25
PT4103178T (pt) 2026-03-30
US20210251972A1 (en) 2021-08-19
EP4103178A4 (en) 2024-03-20
KR20220150902A (ko) 2022-11-11
WO2021163183A1 (en) 2021-08-19
JP2023513700A (ja) 2023-04-03

Similar Documents

Publication Publication Date Title
IL285496A (en) Methods for treating cholestasis
DK4103178T3 (da) Fremgangsmåder til behandling af fabrys sygdom
IL288061A (en) Compounds and methods for the treatment of covid-19
IL282794A (en) Therapeutic methods
IL282881A (en) Methods for treating hepatitis b infection
DK3559265T3 (da) Fremgangsmåde til behandling af polynukleotider
IL261935A (en) Methods of treatment of cholestatic diseases
IL285110A (en) Methods of treating multiple myeloma
DK3286311T3 (da) Fremgangsmåde til behandling af maligniteter
DK3793588T3 (da) Fremgangsmåder til behandling af hæmofili a
DK3393468T3 (da) Fremgangsmåder til behandling af en immundefektsygdom
DK4206308T3 (da) Fremgangsmåde til behandling af lipidmaterialer
IL280140A (en) Antigen purification method
DK3952858T3 (da) Fremgangsmåde til behandling af tumorer
DK3307682T3 (da) Fremgangsmåde til biologisk rensning af spildevand
DK4034122T3 (da) Fremgangsmåder til behandling af hyperfenylalaninæmi
IL281736A (en) Methods of treating myeloproliferative disorders
DK3661510T3 (da) Fremgangsmåder til behandling af adfærdsændringer
IL287130A (en) Methods of treating pruritus
EP4204158C0 (en) PROTEOGLYCAN SPECIFIC PROCESS VALIDATION
DK3326685T3 (da) Cochleaimplantatsystem til behandling af multipel lydkildeinformation
IL286857A (en) Methods for the treatment of beta-thalassemia
IL289436A (en) Methods for treating ocular diseases
IL281589A (en) Methods of treating myeloproliferative disorders
IL281792A (en) Treatment methods